Fred Knoll‘s Knoll Capital Management reported acquiring 526,903 common shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) via a 13G filing recently filed with the US Securities and Exchange Commission. The position represents a new addition to Knoll Capital Management’s portfolio, and the stake accounts for 6.14% of the company’s outstanding stock.
Ritter Pharmaceuticals, is a pharmaceutical company that works on developing therapeutics for treating gastrointestinal disorders. Since the beginning of the year, the company’s stock has gained 4.12%. In its last financial report, for the second quarter, Ritter Pharmaceuticals’ disclosed a net loss of $4.1 million or $0.48 per share, which compares to a loss of $2.3 million or $4.18 per share for the corresponding quarter a year earlier. The company did not generate any revenue during the period.
wavebreakmedia/Shutterstock.com
Among 749 hedge funds from our database, three were bullish on Ritter Pharmaceuticals (NASDAQ:RTTR) at the end of June, same as in the earlier quarter. Those smart money managers were Kevin Kotler‘s Broadfin Capital, which held $1.18 million worth of Ritter Pharmaceuticals’ shares, Julian and Felix Baker’s Baker Bros. Advisors, which owned a position worth $612,000, and Adam Usdan’s Trellus Management Company with a $28,000 worth a position.
Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)
Follow Qualigen Therapeutics Inc. (NASDAQ:QLGN)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Knoll Capital Management | 0 | 526,903 | 0 | 526,903 | 526,903 | 6.14% |
| Fred Knoll | 0 | 526,903 | 0 | 526,903 | 526,903 | 6.14% |
| Gakasa Holdings | 0 | 526,903 | 0 | 526,903 | 526,903 | 6.14% |
Follow Fred Knoll's Knoll Capital Management
Page 1 of 7 – SEC Filing
| UNITED STATES | ||
| SECURITIES AND EXCHANGE COMMISSION | ||
| Washington, D.C. 20549 | ||
| SCHEDULE 13G* | ||
| (Rule 13d-102) | ||
| INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT | ||
| TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED | ||
| PURSUANT TO RULE 13d-2 | ||
| (Amendment No. __) | ||
| Ritter Pharmaceuticals, Inc. | ||
| (Name of Issuer) | ||
| Common Stock, $0.001 par value per share | ||
| (Title of Class of Securities) | ||
| 767836109 | ||
| (CUSIP Number) | ||
| September | ||
| (Date of Event Which Requires Filing of the Statement) | ||
Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☒ | Rule 13d-1(c) |
| ☐ | Rule 13d-1(d) |
*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes)
| Page 1 of 7 |
